Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.48 |
| ▸ | NPC1 | O15118 | 8/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6174368 | 0.93 | KMT2A (0.42) | RAB9ANPC1IKBKBCHUKMEN1 | |
| Hydrochloric Acid SCHEMBL6173338 | 0.87 | RAB9A (0.50) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL6174454 | 0.85 | MAPT (0.44) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL27583802 | 0.84 | KMT2A (0.48) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL27601320 | 0.83 | MEN1 (0.48) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL6174792 | 0.83 | MEN1 (0.48) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL6173268 | 0.83 | RAB9A (0.43) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL6173143 | 0.83 | KMT2A (0.44) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL6171748 | 0.82 | RAB9A (0.43) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL6174882 | 0.82 | POLB (0.49) | RAB9ANPC1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949543-B2 | Amide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-27 | — | — | US | claimed |
| EP-1340750-B1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-08-17 | — | — | EP | claimed |
| US-20040034232-A1 | Amide derivative | ASTELLAS PHARMA INC. (JP) | 2004-02-19 | — | — | US | claimed |
| EP-1340750-A1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-09-03 | — | — | EP | claimed |
| US-20090048310-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ASTELLAS PHARMA INC. (JP) | 2009-02-19 | — | — | US | disclosed |
| US-7465748-B2 | Antiherpesvirus drugs; great pharmacokinetics, good antivirus activity when administered orally at a low dose, high safety profile, less mutagenic concerns; N-(2,6-dimethylphenyl)-N-(2-{[4-(1,3-oxazol-4-yl)phenyl]amino)-2-oxoethyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-7465748-B2 | Antiherpesvirus drugs; great pharmacokinetics, good antivirus activity when administered orally at a low dose, high safety profile, less mutagenic concerns; N-(2,6-dimethylphenyl)-N-(2-{[4-(1,3-oxazol-4-yl)phenyl]amino)-2-oxoethyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-1844776-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | Astellas Pharma Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-6949543-B2 | Amide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-1340750-B1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20040034232-A1 | Amide derivative | ASTELLAS PHARMA INC. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1340750-A1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048310-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ZC3HAV1, ZC3HAV1L, GRIK2 | RAB9A 1654/4885NPC1 2398/4885IKBKB 1644/4885 |
| US-20040034232-A1 | Amide derivative | HDAC2, ZC3HAV1, HDAC4 | RAB9A 1475/4885NPC1 3690/4885IKBKB 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.